Industry news - Propeller Health, Novartis, Astra Zeneca, page-14

That’s going to happen possibly this year with the right news that’s coming. It will shoot up like a skyrocket and even at that price it’s way undervalued. If any potential shareholder does some basic numbers you’ll be gobsmacked at the amount of dollars Respiri will most likely earn and it’s also a business model built on recurring revenue growing month on month year on year! The device is 100% unique to the world as there is nothing like it or even comes near what the device can do for asthmatics!
Helping to SAVE LIVES!
Along with the now excellent management that are totally invested and understand what we have.